SCYNEXIS, Inc. Announces Launch Of Initial Public Offering Of Common Stock

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery and development company SCYNEXIS, Inc., today announced that it plans to commence a road show on March 24, 2014 for the proposed initial public offering of shares of its common stock. SCYNEXIS has filed a registration statement with the Securities and Exchange Commission to offer 4,230,800 shares of its common stock to the public. The initial public offering price is currently expected to be between $12.00 and $14.00 per share. The underwriters have an option to purchase an additional 634,620 shares of common stock at the initial public offering price less the underwriting discount, within 30 days from the date of the offering.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC